Biotechnology News and Research

RSS

St. Jude scientists develop insights to guide development of powerful novel anti-influenza drugs

By analyzing the molecular details of how artificially created drug-resistant flu strains manage to survive treatment, St. Jude Children's Research Hospital scientists have developed insights to guide development of powerful new anti-influenza drugs. These compounds will target a viral enzyme critical to the virus' proliferation in the body.

15 Mar 2016

New drug could transform treatment of metastatic triple negative breast cancer

A team of investigators from Houston Methodist Research Institute may have transformed the treatment of metastatic triple negative breast cancer by creating the first drug to successfully eliminate lung metastases in mice.

15 Mar 2016

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation.

11 Mar 2016

Researchers develop new process for synthesis of potent anti-cancer agents

A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.

10 Mar 2016

Gar genome helps identify genetic sequences shared by human disease genes and zebrafish

Led by Drs John Postlethwait and Ingo Braasch from the Institute of Neuroscience, University of Oregon, US, in collaboration with the Broad Institute, the study of the Spotted Gar (Lepisosteus oculatus) genome reveals that it is small and manageable. Furthermore, it lacks much shuffling and duplication that occurred in the 'main' fish ancestral line; it conserved its genome.

10 Mar 2016

Overprescribing of opioids leads to serious public health problems

Overprescribing of opioids and opioid addiction are serious and growing public health problems in the U.S., and are the focus of a new report by an expert panel, entitled The American Opioid Epidemic: Population Health Implications and Potential Solutions," from the National Stakeholder Panel, Jefferson College of Population Health, which is published in a special supplement to Population Health Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The supplement is available open access on the Population Health Managementwebsite

10 Mar 2016

Mayo Clinic develops 'The ABCs of Influenza' flash cards

Influenza is a serious viral infection that causes illness, hospitalizations and thousands of deaths every year in the U.S. Mayo Clinic recommends getting a vaccine each year to prevent illness and protect the people around you.

9 Mar 2016

Drug-incorporated nanoparticle platforms allow for selective targeting of cancer cells

Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. It is a leading cause of death and the burden is expected to grow worldwide due to the growth and aging of the population, mainly in less developed countries, in which about 82% of the world's population resides. By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths simply due to the growth and aging of the population. Current cancer therapy approaches are based in surgery, radiotherapy and chemotherapy, being the chemotherapy the one that shows the greater efficiency for cancer treatment, mainly in more advanced stages. A major problem with this conventional chemotherapy is its toxicity and it also destroys healthy tissues resulting in systemic toxicity besides beneficial characteristics of killing cancer cells. Anticancer drugs also destroy healthy tissues resulting in systemic toxicity.

8 Mar 2016

Research findings may provide highly effective therapeutic strategy for treatment of Alzheimer's, AMD

For the first time, researchers at LSU Health New Orleans have shown that a protein critical to the body's ability to remove waste products from the brain and retina is diminished in age-related macular degeneration, after first making the discovery in an Alzheimer's disease brain. The research team, led by Walter Lukiw, PhD, Professor of Neurology, Neuroscience and Ophthalmology at LSU Health New Orleans Neuroscience Center, also discovered a key reason, identifying a new treatment target.

8 Mar 2016

NIHR HPRU announces new round of funding to support Zika virus research

A round of funding to support research on the emerging Zika virus was announced this week by the National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections at the University of Liverpool.

8 Mar 2016

Researchers develop new technique to create naïve pluripotent stem cells

Scientists at the University of Cambridge have for the first time shown that it is possible to derive from a human embryo so-called 'naïve' pluripotent stem cells - one of the most flexible types of stem cell, which can develop into all human tissue other than the placenta.

7 Mar 2016

Luminex collaborates with University of São Paulo to validate multi-analyte Zika virus assay

Luminex Corporation today announced it is collaborating with the Laboratory of Molecular Evolution & Bioinformatics, Biomedical Sciences Institute, University of São Paulo, Brazil to validate a multi-analyte Zika virus assay developed by Luminex partner, GenArraytion, Inc.

26 Feb 2016

China Biologic's total sales increase by 22.6% in RMB terms to $68.3 million in Q4 2015

China Biologic Products, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2015.

26 Feb 2016

Insulet partners with Mode AGC to develop OmniPod Artificial Pancreas system

Insulet Corporation, the leader in tubeless insulin pump technology with its OmniPod Insulin Management System (OmniPod System), today announced a license agreement and partnership with Mode AGC (Automated Glucose Control LLC), to develop and incorporate the advanced artificial pancreas algorithm created by renowned researchers Francis Doyle PhD, Eyal Dassau PhD, and Howard Zisser MD.

25 Feb 2016

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA).

25 Feb 2016

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Asterias Biotherapeutics, Inc. today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML).

24 Feb 2016

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Researchers at the Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona (IBB-UAB), in collaboration with the biopharmaceutical company SOM Biotech, located in the Barcelona Science Park (PCB), have published, in Nature Communications, the results of a drug repositioning study in which they describe a powerful drug, SOM0226 (tolcapone) that could significantly improve the pharmacological treatment of familial transthyretin amyloidosis (ATTR).

24 Feb 2016

Researchers develop designer recombinase that can remove provirus from HIV-1 isolates

Researchers at the Medical Faculty of the Technische Universität Dresden and the Heinrich Pette Institute, Leibniz Institute for Experimental Virology succeeded in developing a designer recombinase (Brec1) that is capable of specifically removing the provirus from infected cells of most primary HIV-1 isolates.

23 Feb 2016

Researchers devise new approach to improve current T-cell therapy methods

T-cell therapy, a form of immunotherapy that uses a patient's own immune cells to attack their cancer, has been making waves recently. The "living" therapy involves engineering the patient's T cells in the laboratory to carry new proteins that guide the immune cells directly to tumor cells, allowing the engineered T cells to attack and kill the cancer.

23 Feb 2016

PharmaEssentia to present results of P1101 + ribavirin phase II trial in HCV patients at APASL 2016

PharmaEssentia Corporation announces presentation of the results of the phase II trial for P1101 + ribavirin in patients with chronic HCV genotype 1 infection at the 25th Conference of the Asian Pacific Association for the Study of the Liver, taking place in Tokyo, Japan from February 20 to 24, 2016 (APASL 2016). Data will be presented by the study coordinating investigator Prof. Wan-Long Chuang (Taiwan) at the HCV parallel oral session on Feb 22nd (15:45-17:45).

22 Feb 2016

Biotechnology News and Research

St. Jude scientists develop insights to guide development of powerful novel anti-influenza drugs

New drug could transform treatment of metastatic triple negative breast cancer

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

Researchers develop new process for synthesis of potent anti-cancer agents

Gar genome helps identify genetic sequences shared by human disease genes and zebrafish

Overprescribing of opioids leads to serious public health problems

Mayo Clinic develops 'The ABCs of Influenza' flash cards

Drug-incorporated nanoparticle platforms allow for selective targeting of cancer cells

Research findings may provide highly effective therapeutic strategy for treatment of Alzheimer's, AMD

NIHR HPRU announces new round of funding to support Zika virus research

Researchers develop new technique to create naïve pluripotent stem cells

Luminex collaborates with University of São Paulo to validate multi-analyte Zika virus assay

China Biologic's total sales increase by 22.6% in RMB terms to $68.3 million in Q4 2015

Insulet partners with Mode AGC to develop OmniPod Artificial Pancreas system

Rigel begins fostamatinib Phase 2 trial for treatment of patients with autoimmune hemolytic anemia

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Researchers develop designer recombinase that can remove provirus from HIV-1 isolates

Researchers devise new approach to improve current T-cell therapy methods

PharmaEssentia to present results of P1101 + ribavirin phase II trial in HCV patients at APASL 2016

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News